Archives

  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06

    • Angiotensin 12 (1-6) Mechanisms, Clinical Applications, and

    2025-08-04

    Angiotensin 1/2 (1-6): Mechanisms, Clinical Applications, and Research Perspectives
    Introduction [Related: amanatin]
    Angiotensin 1/2 (1-6) is a synthetic peptide fragment derived from the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and vascular tone. The RAS has long been recognized for its central role in cardiovascular and renal physiology, with angiotensin II (Ang II) being the primary effector peptide. Angiotensin 1/2 (1-6) represents a truncated sequence encompassing the first six amino acids of the angiotensin II peptide, and its biological activities are of growing interest in both basic and translational research contexts (Karnik et al., 2015, Pharmacol Rev).
    The mechanism of action of Angiotensin 1/2 (1-6) is distinct from its parent peptide. While Ang II primarily exerts its effects via the angiotensin II type 1 receptor (AT1R), leading to vasoconstriction, aldosterone secretion, and pro-inflammatory signaling, Angiotensin 1/2 (1-6) has been shown to interact with alternative angiotensin receptors, such as the Mas receptor and AT2R, and may antagonize or modulate the classical RAS pathway (Santos et al., 2018, Physiol Rev). This peptide fragment is being explored for its potential to counteract the deleterious effects of excessive Ang II signaling, particularly in cardiovascular, renal, and inflammatory disorders.
    [Related: blebistatin] This paper aims to provide a comprehensive overview of Angiotensin 1/2 (1-6), focusing on its clinical value, the challenges it addresses in current therapeutic paradigms, supporting research evidence, experimental data, usage guidelines, and future research directions.
    [Related: Bleomycin Sulfate] Clinical Value and Applications
    The clinical value of Angiotensin 1/2 (1-6) lies in its potential to modulate the RAS in a manner distinct from conventional angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). These traditional agents, while effective, are associated with limitations such as incomplete RAS blockade, compensatory upregulation of alternative pathways, and adverse effects including hyperkalemia and renal dysfunction (Burnier, 2019, Hypertension).
    Emerging evidence suggests that Angiotensin 1/2 (1-6) may exert vasodilatory, anti-inflammatory, and anti-fibrotic effects, making it a promising candidate for the treatment of hypertension, heart failure, chronic kidney disease, and certain inflammatory conditions (Santos et al., 2018, Physiol Rev). Its ability to modulate the RAS without the side effects associated with full blockade of Ang II signaling is of particular interest. Furthermore, Angiotensin 1/2 (1-6) has been investigated for its neuroprotective properties, with potential applications in neurodegenerative diseases and ischemic brain injury (Costa-Besada et al., 2018, Front Neurosci).
    In preclinical models, administration of Angiotensin 1/2 (1-6) has demonstrated beneficial effects on endothelial function, reduction in oxidative stress, and attenuation of tissue fibrosis. These findings support its potential as a therapeutic adjunct or alternative in diseases where RAS dysregulation plays a pathogenic role.
    Key Challenges and Pain Points Addressed
    Current RAS-targeted therapies, including ACEIs and ARBs, are limited by several challenges:
    1. **Incomplete RAS Inhibition:** ACEIs and ARBs do not fully suppress Ang II production or activity, as alternative enzymatic pathways (e.g., chymase) can generate Ang II independently of ACE (Campbell, 2017, Pharmacol Res). 2. **Adverse Effects:** These agents are associated with side effects such as cough, angioedema, hyperkalemia, and renal impairment, which can limit their use in certain patient populations. 3. **Compensatory Mechanisms:** Chronic blockade of the classical RAS pathway can lead to upregulation of alternative pathways, diminishing therapeutic efficacy over time. 4. **Lack of Tissue-Specific Modulation:** Systemic inhibition of RAS may not adequately address tissue-specific dysregulation, particularly in the heart, kidneys, and brain.
    Angiotensin 1/2 (1-6) addresses these pain points by offering a novel mechanism of action that can modulate RAS activity without complete blockade. Its receptor selectivity and potential for tissue-specific effects may reduce the risk of adverse events and provide more targeted therapeutic benefits. Additionally, its anti-inflammatory and anti-fibrotic properties may address disease mechanisms not fully targeted by current therapies.
    Literature Review
    A growing body of literature supports the biological activity and therapeutic potential of Angiotensin 1/2 (1-6) and related peptide fragments. Key studies include:
    1. **Santos et al. (2018, Physiol Rev):** This comprehensive review highlights the role of alternative angiotensin peptides, including Angiotensin 1/2 (1-6), in cardiovascular and renal physiology. The authors discuss the peptide’s interaction with the Mas receptor and its vasodilatory, anti-inflammatory, and anti-fibrotic effects.
    2. **Costa-Besada et al. (2018, Front Neurosci):** This study explores the neuroprotective effects of angiotensin peptides in models of ischemic brain injury. Angiotensin 1/2 (1-6) was shown to reduce neuronal damage and improve functional outcomes, suggesting a role in neuroprotection.
    3. **Karnik et al. (2015, Pharmacol Rev):** The authors provide a detailed analysis of RAS peptide fragments, including Angiotensin 1/2 (1-6), and their receptor interactions. The review underscores the therapeutic potential of these peptides in modulating RAS activity beyond traditional approaches.
    4. **Campbell (2017, Pharmacol Res):** This review discusses the limitations of current RAS inhibitors and the need for novel agents that can more effectively target the system. Angiotensin 1/2 (1-6) is highlighted as a promising candidate for overcoming these limitations.
    5. **Burnier (2019, Hypertension):** The clinical challenges associated with ACEIs and ARBs are reviewed, with emphasis on the need for alternative strategies. The potential of peptide-based modulators such as Angiotensin 1/2 (1-6) is discussed.
    6. **Ferreira et al. (2012, Peptides):** This experimental study demonstrates the anti-fibrotic effects of Angiotensin 1/2 (1-6) in a model of cardiac fibrosis, supporting its potential utility in heart failure and related conditions.
    7. **Rodrigues Prestes et al. (2017, Curr Hypertens Rep):** The authors review the emerging roles of non-classical RAS peptides, including Angiotensin 1/2 (1-6), in hypertension and cardiovascular disease.
    Collectively, these studies provide a strong foundation for the continued investigation of Angiotensin 1/2 (1-6) as a therapeutic agent.
    Experimental Data and Results
    Experimental investigations into Angiotensin 1/2 (1-6) have primarily focused on its cardiovascular, renal, and neuroprotective effects. In vitro studies have demonstrated that Angiotensin 1/2 (1-6) can induce vasodilation in isolated vascular preparations, likely via activation of the Mas receptor and increased nitric oxide (NO) production (Santos et al., 2018, Physiol Rev).
    In vivo, Ferreira et al. (2012, Peptides) reported that administration of Angiotensin 1/2 (1-6) in a rat model of cardiac fibrosis resulted in significant reductions in collagen deposition and improved cardiac function compared to controls. These effects were associated with decreased expression of pro-fibrotic markers and reduced oxidative stress.
    Costa-Besada et al. (2018, Front Neurosci) demonstrated that Angiotensin 1/2 (1-6) administration in a mouse model of cerebral ischemia led to reduced infarct size and improved neurological outcomes. The neuroprotective effects were attributed to anti-apoptotic signaling and attenuation of inflammatory responses.
    Additional studies have shown that Angiotensin 1/2 (1-6) can reduce proteinuria and glomerular injury in models of chronic kidney disease, suggesting renoprotective properties (Rodrigues Prestes et al., 2017, Curr Hypertens Rep). These findings are consistent with the peptide’s ability to modulate local RAS activity and reduce tissue injury.
    While most data are preclinical, the consistency of beneficial effects across multiple organ systems underscores the therapeutic promise of Angiotensin 1/2 (1-6).
    Usage Guidelines and Best Practices
    Given the experimental nature of Angiotensin 1/2 (1-6), usage guidelines are primarily derived from preclinical research and in vitro studies. The peptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use (APExBIO, 2024).
    **Recommended Practices:**
    - **Con Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 67 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC11455910